Genenta Science shares surge 10.71% premarket as TEM-GBM study shows 44% 18-month survival rate and expansion into renal cell carcinoma trials.

Genenta Science surged 10.71% in premarket trading following an update on its TEM-GBM study for glioblastoma, highlighting improved 18-month survival rates (44% vs. 38%) and a patient achieving three-year survival without additional treatment. The company also announced expansion into a Phase 1/2a trial for metastatic renal cell carcinoma, reinforcing its oncology pipeline. Additionally, Genenta reported $30 million in cash reserves post-funding, bolstering confidence in its ability to advance clinical programs. These developments underscored progress in Temferon’s potential to alter survival outcomes in aggressive cancers, driving investor optimism.